英赛生泵 PODD

Ms. McEvoy has served on our Board and as our President and Chief Executive Officer since April 2025. She is the former Executive Vice President, Worldwide Chairman of MedTech at Johnson & Johnson, a position she held from 2018 to 2023. In this role, Ms. McEvoy had responsibility for the company's surgery, orthopaedics, interventional solutions, and eye health businesses. During her tenure at J&J, Ms. McEvoy led significant and diverse businesses with a global footprint, driving strategic investments in innovation platforms and commercial executions that delivered significant growth for J&J's MedTech business. At J&J, Ms. McEvoy was Company Group Chairman, Consumer Medical Devices from 2014 to 2018 and Company Group Chairman, Vision Care from 2012 to 2014. Ms. McEvoy also led J&J's global suture products business as Worldwide President, Ethicon Products from 2009 to 2011, served as President, McNeil Consumer Healthcare from 2006 to 2009, and served as Vice President, Marketing and General Manager, McNeil Labs from 2003 to 2006. She joined J&J in 1996 as an Assistant Brand Manager, having previously worked in advertising at both Grey Advertising and J. Walter Thompson (now Wunderman Thompson). Ms. McEvoy previously served on the Board of Trustees of the Children's Hospital of Philadelphia. Ms. McEvoy earned a Bachelor of Arts in Communications and Business from the University of Pennsylvania. Other current public company boards - The Procter and Gamble Company.

Ms. Pease has served as our Executive Vice President and Chief Financial Officer since September 2025. She previously served on our Board of Directors from January 2024 through September 2025. Prior to joining Insulet as CFO, from 2022 to 2025, she was the Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories. Prior to joining Charles River, from 2019 to 2022, Ms. Pease served as Vice President and Group Chief Financial Officer of Johnson & Johnson's global Medical Devices businesses. With more than 20 years in financial leadership roles at J&J, Ms. Pease has developed deep knowledge and experience managing the finance organizations of large, growing businesses in the healthcare industry. From 2016 to 2019, Ms. Pease was Vice President, Finance for Janssen North America, J&J's Pharmaceutical business in the United States and Canada. Previously, from 2014 to 2016, Ms. Pease was Vice President of the Enterprise Program Management Office, responsible for supporting J&J's executive management team with the strategic planning process and the advancement of enterprise growth initiatives. From 2009 to 2012, she led the integration of the Mentor and Acclarent acquisitions as a Vice President of Finance and subsequently became the Vice President of Finance for Janssen Supply Chain from 2012 to 2014. Ms. Pease began her career at J&J in 1998 with the LifeScan business and subsequently held finance leadership positions within Mergers and Acquisitions Analysis and J&J Medical Brazil. Prior to joining J&J, Ms. Pease worked for SC Johnson and an investment bank in Brazil. Ms. Pease earned a Bachelor of Science (Bacharel em Ciencias) in Economics from the Pontificia Universidade Catolica in Rio de Janeiro, Brazil and a Master of Business Administration from Santa Clara University Leavy School of Business.

Mr. Benjamin has served as our Chief Operating Officer since August 2025. Mr. Benjamin previously served as our Chief Product and Customer Experience Officer from July 2023 until his promotion to Chief Operating Officer. From March 2022 to June 2023, he served as our Executive Vice President, Innovation, Strategy and Digital Products, and from February 2020 to March 2022, he served as our Senior Vice President, Innovation and Strategy. From May 2015 to February 2020, he served in roles of increasing responsibility at Insulet, including, Senior Vice President, R&D, New Product Development and Commercialization; Vice President, Procurement and Supplier Development; and Director, Business Development. Prior to joining Insulet, Mr. Benjamin held roles of increasing responsibility spanning R&D, Manufacturing, and Quality with Abbott Laboratories. He earned a Bachelor of Science in Industrial Engineering and Operations Research from the University of California at Berkeley, a Master of Engineering in Bioengineering from the University of California at San Diego, and a Master of Business Administration from Harvard Business School.

Mr. Kapples has served as our Senior Vice President and General Counsel since March 2019 and Secretary from March 2019 to December 2021. From 2015 to 2019, he served as Vice President, General Counsel and Secretary at GCP Applied Technologies, Inc. From 2006 to 2015, Mr. Kapples served as Vice President and Corporate Secretary of Covidien plc, which was acquired by Medtronic plc in 2015. At Covidien, he was responsible for building the Company's legal structure and governance framework, as well as advising on strategic transactions and global partnerships. From 1994 to 2006, Mr. Kapples served in various roles of increasing responsibility at Raytheon Company, including Assistant General Counsel and Secretary, and from 1985 to 1993 he was a Corporate Associate at Sullivan & Worcester LLP. Mr. Kapples earned both his Bachelor of Arts in English and his Juris Doctor from Georgetown University. He is a member of the Massachusetts Bar Association.

Mr. Singh has served as our Senior Vice President, Global Operations since January 2023. From December 2021 through December 2022, he served as our Group Vice President, Head of Global Supply Chain Operations where led our efforts to ensure component availability and improve supply chain efficiency to increase manufacturing capacity. From 2016 and until he joined Insulet in 2021, Mr. Singh served as Vice President of Operations and Quality for the Chromatography and Mass Spectrometry Division at Thermo Fisher Scientific Inc. Previously, he spent 18 years at General Electric in various roles of increasing responsibility within global operations and end-to-end supply chain, including as General Manager of Global Supply Chain Operations for GE Inspection Technologies. Mr. Singh earned a Bachelor of Science in Finance and Marketing from Boston College and he is a Certified Six Sigma Master Black Belt.

Dr. Frederick has served on our Board of Directors since October 2020. Since September 2025, he has served as Interim President of Howard University. Dr. Frederick is the President Emeritus of Howard University, having previously served as the President from July 2014 to September 2023. From November 2024 to August 2025, Dr Frederick was the Interim Chief Executive Officer of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Dr. Frederick is also the distinguished Charles R. Drew Professor of Surgery at the Howard University College of Medicine. Prior to being appointed President of Howard in 2014, Dr. Frederick served as Howard's Provost and Chief Academic Officer. Dr. Frederick is a practicing cancer surgeon, distinguished researcher and scholar, and the author of numerous peer-reviewed articles, book chapters, abstracts, and editorials. A widely recognized expert in the fields of health care disparities and medical education, his medical research focuses on reducing racial, ethnic, and gender disparities in cancer care outcomes, with a particular emphasis on gastrointestinal cancers. Throughout his career, Dr. Frederick has received numerous recognitions, including the Distinguished Alumnus Award from the University of Texas MD Anderson Cancer Center. In 2021, he was recognized by the Carnegie Corporation of New York as one of 34 naturalized citizens honored for their contributions to strengthening the United States. Dr. Frederick currently serves on the boards of Agostini Limited, Humana, Inc., Tempus AI, Inc. and Workday, Inc. and served on the American Cancer Society Board before assuming the role of Interim Chief Executive Officer. He is an active member of several professional associations, including the American Surgical Association and the American College of Surgeons. Recently, he was appointed senior independent director of Mutual of America and also serves as Senior Advisor for Blackstone Inc. He received his Bachelor of Science, Doctor of Medicine, and Master of Business Administration from Howard University. Former public company boards - Forma Therapeutics Holdings, Inc.

Elizabeth Weatherman has served on our Board of Directors since February 2022 and as our Board Chair since December 2025. She has been a Special Limited Partner of Warburg Pincus since January 2016. Ms. Weatherman joined Warburg Pincus in 1988 and led the firm's Healthcare Group from 2008 to 2015, serving as a Managing Director and a member of the firm's Executive Management Group. Ms. Weatherman serves as a director of Royalty Pharma, as a director of Stanford Health Care, as a trustee of Stanford University and as a trustee and chair of the Investment Committee of Mount Holyoke College. Ms. Weatherman earned a BA in English from Mount Holyoke College and an MBA from the Stanford Graduate School of Business. Former public company boards - Nevro Corp., Silk Road Medical, Inc., Vapotherm, Inc., Wright Medical Group, N.V.

Mr. Stonesifer has served on our Board of Directors since January 2024. Since April 2019, he has been the Chief Financial Officer at Alcon Inc. Prior to joining Alcon, he served as Executive Vice President and Chief Financial Officer at Hewlett Packard Enterprise Corporation from November 2015 through September 2018. Prior to that role, Mr. Stonesifer was the Senior Vice President and Chief Financial Officer, Enterprise Group at HP since 2014. Before joining HP, he served as Chief Financial Officer of General Motors' International Operations from 2011 to 2014. Previously, he served as Chief Financial Officer of Alegco Scotsman, a storage company, from 2010 to May 2011; Chief Financial Officer of Sabic Innovative Plastics (formerly GE Plastics) from 2007 to 2010; and various other positions at General Electric since joining the company in 1989. Mr. Stonesifer holds a Bachelor of Arts in Economics from the University of Michigan.

Dr. Borio, who is NACD Directorship certified, has served on our Board of Directors since October 2021. She is a venture partner at ARCH Venture Partners (ARCH) where she advises on new investment opportunities related to drugs and biologics manufacturing, clinical trials, novel therapies, and areas with large unmet clinical needs. Dr. Borio is also an adjunct faculty member at Johns Hopkins Hospital and a senior fellow for Global Health at the Council on Foreign Relations. Dr. Borio is a specialist in biodefense, emerging infectious diseases, medical product development, and complex public health emergencies. In 2020, she served as a member of the President's Transition COVID-19 Advisory Board. From 2019 to 2020, Dr. Borio was Senior Vice President at In-Q-Tel, an independent, non-profit, strategic investment firm. From 2017 to 2019, she was Director for Medical and Biodefense Preparedness Policy at the National Security Council. From 2009 to 2017, Dr. Borio held roles of increasing responsibility at the U.S. Food and Drug Administration, including Acting Chief Scientist and Assistant Commissioner for Counterterrorism Policy. While at the FDA, Dr. Borio helped develop and execute the FDA's medical countermeasures and public health responses to the 2009 H1N1 flu pandemic, the 2014 Ebola epidemic, and the 2015 Zika outbreak. Dr. Borio also served on the World Health Organization's Emergency Preparedness and Response Scientific Advisory Group. She earned a Doctor of Medicine from George Washington University School of Medicine and a Bachelor of Science in Zoology from George Washington University. Other current public company boards - Eagle Pharmaceuticals, Inc.

Dr. Hopfield, who is NACD Directorship certified, has served on our Board of Directors since July 2015 and served as our Lead Independent Director from August 2016 through December 2018. Dr. Hopfield is a distinguished healthcare executive and diabetes expert with over two decades of experience in the medical and healthcare fields. She is a strategic advisor and investor in healthcare and technology firms seeking to commercialize innovative intellectual property. Since 2010, Dr. Hopfield has been the principal at J Hopfield Consulting, providing guidance and executive coaching to start-up technology firms. She is the former Chair of the Board of Trustees of the Joslin Diabetes Center. From 1995 to 2009, Dr. Hopfield was a Partner at McKinsey & Company in their global pharmaceuticals and medical devices practice where she served clients across the pharmaceutical, biotech, medical device and consumer industries with a focus on strategy, R&D management and marketing. She also previously held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing. Dr. Hopfield serves on the Board of Directors of Editas Medine, a gene editing company focused on developing transformative medicines. She previously served on the Board of Directors of Maravai LifeSciences Holdings, Inc., PhenomeX Inc. and Radius Health, Inc. Dr. Hopfield earned a Bachelor of Science from Yale College, an MBA from the Harvard Business School as a Baker Scholar, and a Doctor of Philosophy in Neuroscience/Biochemistry from The Rockefeller University.

Mr. Huffines has served on our Board of Directors since October 2025. Mr. Huffines is the co-founder of The Forest Group, a nonprofit organization dedicated to improving the mental health of children in underserved communities. From 2017 to 2024, Mr. Huffines served as global chair, investment banking of J.P. Morgan Chase & Co., a global financial services firm. From 2011 to 2017, he was the vice chair of investment banking and from 2002 to 2010, he was the co-head of the global healthcare investment banking group at J.P. Morgan. From 1992 to 2002, Mr. Huffines served in various positions in the healthcare mergers and acquisitions and healthcare industry groups at J.P. Morgan. Prior to joining J.P. Morgan, Mr. Huffines worked at Alex Brown & Sons, specializing in equity financing and advisory assignments for emerging growth companies. He is currently a member of the board of directors of Becton, Dickinson and Company, a global medical technology company, Eikon Therapeutics, a California-based biotechnology company, the Hastings Center for Biomedical Ethics, an independent, non-profit, nonpartisan bioethics research institute, and Nextech Invest Ltd., a cancer-focused venture capital firm headquartered in Zurich, Switzerland. Mr. Huffines previously served on the Board of Directors of Walgreens Boots Alliance. Mr. Huffines earned an M.B.A. from the University of Virginia Darden School of Business, where he received the Faculty Award for academic excellence, and a B.A. from the University of North Carolina at Chapel Hill in English and Economics.

On June 24, 2026, the Board of Directors of Insulet Corporation appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. Mr. Mazelsky currently serves as Executive Chair of the board of directors of IDEXX Laboratories, Inc., a global leader in animal health diagnostics and software that equips veterinarians with integrated tools and insights to improve care, efficiency, and outcomes for patients worldwide. During Mr. Mazelsky's 14-year tenure as an executive at IDEXX, he served as President and Chief Executive Officer from October 2019 to May 2026, Interim President and Chief Executive Officer from June 2019 to October 2019, and Executive Vice President responsible for IDEXX's North American Companion Animal Group Commercial Organization and key elements of its innovation portfolio, from August 2012 to June 2019. Under Mr. Mazelsky's leadership as CEO, IDEXX revenues and the stock price nearly doubled. Before joining IDEXX, Mr. Mazelsky served as Senior Vice President and General Manager, Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now Royal Philips), from 2010 to 2012. He also served in various strategic leadership roles at Philips from 2001 to 2010. Prior to joining Philips, Mr. Mazelsky operated in roles at Agilent Technologies, where he was Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips, and General Manager of Agilent's Medical Consumables Business Unit from 1997 to 2000. Earlier in his career, he worked in finance, marketing, and business planning at Hewlett Packard from 1988 to 1996. Mr. Mazelsky currently serves on the board of directors of Dentsply Sirona Inc. He holds an M.B.A. from the University of Chicago Booth School of Business and a B.A. in Mathematics from the University of Rochester.

Mr. Panos has served as our Executive Vice President, Chief Commercial Officer since March 2026. Mr. Panos is an accomplished sales commercial and business leader, most recently, from November 2023 to March 2026, as a Leader of Sales Excellence at Stryker Corporation. Mr. Panos began his career at Stryker, and during his 30-year tenure held product marketing and sales roles of increasing responsibility, including President of the Trauma and Extremities Division from January 2021 to November 2023 and President of North America and Global R&D for the same division from November 2019 to January 2021. Mr. Panos earned both his B.A. in English his M.Ed. in Secondary Education from Boston College.

Ms. Davis has served as our Senior Vice President and Chief Human Resources Officer since July 2025. She is a seasoned global HR executive with over 30 years of experience at Johnson & Johnson, where she led complex business transformations and talent strategies across multi-billion-dollar business units, most recently, from 2018 to 2025, as Vice President of Human Resources for J&J MedTech. In 1994, Ms. Davis began her career at J&J in commercial sales and during her tenure held various HR and leadership roles across the organization's pharmaceutical, consumer, and medical device sectors. She serves on the Board of Governors for Florida State University's College of Business. She earned a Bachelor of Science in Finance from Florida State University and a Master of Business Administration from the University of Florida.